Bipolar Disorder: Can Competitive Advantage Be Established in a Challenging Market

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Overview of Bipolar Disorder
  • Symptoms, Pathophysiology, and Etiology
  • Types of Bipolar Disorder
  • Diagnosis, Epidemiology, and Impact of Bipolar Disorder
• Current Pharmacological Therapies for Bipolar Disorder
  • Lithium
  • Antiepileptic Agents
  • Antipsychotic Agents
  • Antidepressants
• Does Approval Aid Adoption?
• Emerging Therapies for Treatment of Bipolar Disorder
  • Emerging Antipsychotic Agents
    • Janssen’s Invega Extended-Release Tablets
    • Organon’s Asenapine
    • Solvay’s/Wyeth’s/Lundbeck’s Bifeprunox
    • Vanda Pharmaceuticals’ Iloperidone
  • Sodium- and Calcium-Channel Modulators in Development for Bipolar Disorder
    • Novartis’s Licarbazepine (LIC-477)
    • Memory Pharmaceuticals’ MEM-1003
  • Novel Approaches to the Treatment of Bipolar Disorder
• Outlook for the Bipolar Disorder Market

Tables:

• 1. Agents Commonly Used to Treat Bipolar Disorder, 2006
• 2. Emerging Agents for the Treatment of Bipolar Disorder
• 3. Sales of Leading Agents to Treat Bipolar Disorder, 2006

Figures:

• 1. Prevalent Cases of Bipolar Disorder by Type in the Major Markets, 2006
• 2. U.S. Sales of Antipsychotics Used in the Treatment of Bipolar Disorder
• 3. U.S. Prescriptions of Antipsychotics Used in the Treatment of Bipolar Disorder
• 4. U.S. Sales of Antiepileptics Used in the Treatment of Bipolar Disorder
• 5. U.S. Prescriptions of Antiepileptics Used in the Treatment of Bipolar Disorder
• 6. Regional Shares of Bipolar Disorder Treatment Sales in the Major Markets, 2006